{"filings":[{"id":1694357,"accession_number":"0001493152-26-033593","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-07-16T21:30:15+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioRestorative CEO and CFO resign; board appoints new CEO, investigates employment agreements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Lance Alstodt and CFO Robert Kristal resigned July 13, 2026, claiming 'Good Reason' under alleged Change in Control; seek ~$2.85M aggregate severance plus equity acceleration.","Board appointed director Katharyn Field as CEO, President, and interim CFO; she also serves as CEO of iSpecimen (ISPC).","Board elected Esha Randhawa and Steven Brown as new directors; committees reconstituted with new chairs.","Board authorized investigation into negotiation and approval of employment agreements; no severance payments pending outcome.","Employment agreements amended July 8, 2026 to limit change-in-control severance to only certain transaction types."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-16","daily_digest_url":"/daily/2026-07-16","daily_digest_rank":1},{"id":1029445,"accession_number":"0001021771-26-000093","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-06-12T21:00:17+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioRestorative Therapies extends VP R&D Silva's employment; $575K salary unchanged, term to June 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New employment agreement for VP R&D Francisco Silva, effective June 10, 2026, with term through June 10, 2029.","Salary remains at $575,000 per year; eligible for annual discretionary bonus up to 50% of salary.","On termination without cause or resignation for good reason, severance equals 1.5x (salary + max bonus), plus COBRA paid for 1.5 years, and full vesting of equity awards.","Non-compete and non-solicitation covenants apply for 1 year post-termination within US in stem-cell based therapies and biocosmeceuticals.","Agreement includes assignment of all developments and inventions related to company's business as work made for hire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1029316,"accession_number":"0001021771-26-000091","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-06-12T20:56:39+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"BioRestorative Therapies enters $1M revolving loan at 12% with Bowery Group; board overhaul with 3 new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Entered $1,000,000 revolving loan agreement with Bowery Group LLC at 12% interest, 16% default rate, 1-year maturity.","Three directors (Francisco Silva, Nickolay Kukekov, Patrick F. Williams) resigned effective June 11, 2026.","Lender designees Mika Grasso, Katharyn Field, Jatinder Dhaliwal appointed to board as Class II, I, III directors respectively.","Loan proceeds for general corporate purposes; lender controls board composition via appointment rights.","Mr. Grasso chairs Audit Committee; Ms. Field chairs Nominating; Mr. Dhaliwal on all three committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748796,"accession_number":"0001021771-26-000084","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-05-29T21:07:05+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BRTX shareholders approve 20x increase in authorized shares; CEO/CFO sign 3-year employment agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.","CFO Robert Kristal signed 3-year employment agreement with $350k annual salary, unchanged.","Shareholders approved increase in authorized common shares from 75M to 1.5B (20x).","Vote: 9,868,606 for, 2,389,059 against, 179,207 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93260,"accession_number":"0001021771-26-000068","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioRestorative Therapies approves 2025 executive bonuses; CEO bonus $300K, VP $287.5K, CFO $140K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Lance Alstodt awarded $300K cash bonus and $1.5M in option awards; total 2025 compensation $2.4M.","VP Francisco Silva gets $287.5K bonus plus $1.47M in options; total 2025 comp $2.3M.","CFO Robert Kristal awarded $140K bonus and $318K in options; total 2025 comp $801,750.","All bonuses are discretionary for 2025 services, payable in 2026; total compensation up significantly from 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93259,"accession_number":"0001021771-26-000058","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies posts updated corporate presentation; no financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation made available on company website on April 23, 2026.","Presentation intended for use at conferences and investor meetings.","No material new financial or operational data provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104733,"accession_number":"0001493152-26-006837","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.","Gross proceeds ~$5.0M net of ~7% placement agent fee and expenses.","Proceeds to fund BRTX-100 Phase 2 trial, ThermoStem R&D, biocosmeceuticals platform, and working capital.","Rodman & Renshaw acted as exclusive placement agent; 90-day lockup on new equity issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121017,"accession_number":"0001021771-25-000148","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies reports Q3 2025 results; press release content omitted from filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated November 12, 2025, announced Q3 2025 financial results and business update.","Conference call scheduled to discuss results, but no dial-in details specified in the filing.","Full financial figures and operational highlights are not extractable from the provided exhibit text.","No specific revenue, EPS, or segment data available for investor analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":340100.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121016,"accession_number":"0001493152-25-017446","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies raises $1.085M in registered direct offering at $1.60/share; warrants at $2.75","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 678,125 shares at $1.60/share, gross proceeds $1.085M; closing expected Oct 8, 2025.","Concurrent private placement of warrants for 508,594 shares at $2.75 exercise price, 75% warrant coverage, exercisable after 6 months for 5 years.","Offering priced at $1.60/share, above October 3 close of $1.50.","Net proceeds to fund BRTX-100 clinical trials, ThermoStem R&D, biocosmeceuticals platform, and working capital.","CEO notes participation from largest institutional shareholder and management team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137637,"accession_number":"0001021771-25-000131","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioRestorative Therapies shareholders elect directors, approve stock plan amendment, ratify auditor, okay exec pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Francisco Silva (1.59M for) and David Rosa (1.47M for) as Class II directors; ~3.33M broker non-votes.","Approved amendment to 2021 Stock Incentive Plan boosting authorized shares from 6.85M to 9.85M (1.34M for, 289K against).","Ratified CBIZ CPAs as independent auditor for FY2025: 4.72M for, 271K against, 4,864 abstentions.","Advisory vote on executive compensation passed: 1.54M for, 107K against, 19,855 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137636,"accession_number":"0001021771-25-000116","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies releases updated corporate presentation; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation posted on company website and furnished as Exhibit 99.1.","Presentation may be used at upcoming conferences and investor meetings.","No specific financial or operational updates were disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137635,"accession_number":"0001021771-25-000113","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies issues Q2 2025 earnings; no figures in provided excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated Aug 12, 2025 announces Q2 financial results and a business update.","Conference call scheduled to discuss the results; details in the press release.","Specific revenue, EPS, and segment data not included in the filing text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":328300.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154997,"accession_number":"0001021771-25-000092","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.","Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).","No serious adverse events or dose-limiting toxicities reported between 26 and 104 weeks at target dose of 40 million cells.","Number of evaluated subjects increased from 15 to 36 since last update; FDA requires >30% improvement thresholds.","CEO Lance Alstodt expressed confidence BRTX-100 can meet or exceed FDA thresholds for function and pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154996,"accession_number":"0001021771-25-000079","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies issues Q1 2025 results press release; financial details not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced Q1 2025 financial results and business update on May 14, 2025.","Press release references a conference call to discuss results, but specific figures are not included in the filing.","No EPS, revenue, or segment data were disclosed in the submitted Form 8-K exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":25000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154995,"accession_number":"0001021771-25-000074","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.","CBIZ CPAs P.C. appointed as new independent registered public accounting firm by Audit Committee on same date.","No disagreements with Marcum on accounting principles or audit scope during past two fiscal years and subsequent interim.","Material weaknesses in internal control over financial reporting persisted in FY2024 and FY2023, as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173511,"accession_number":"0001021771-25-000066","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies to release FY2024 results after market close on March 27, 2025, with conference call","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Financial results for year ended Dec 31, 2024 will be released after market close on March 27, 2025.","Management will host a conference call following the release to review results and provide a business update.","Conference call details (dial-in, replay) were not included in the filing; no financial figures provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173510,"accession_number":"0001021771-25-000031","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies presents at ORS 2025; VP Silva discusses development programs","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Francisco Silva, VP of R&D, presented at Orthopaedic Research Society 2025 Annual Meeting on Feb 8.","Presentation materials will be posted on company website for 90 days under Scientific Publications.","No financial or clinical results from the presentation disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190498,"accession_number":"0001021771-24-000195","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).","Cash & equivalents $13.1M, no debt as of Sep 30, 2024.","$230,700 product revenue from Cartessa Aesthetics supply agreement in Q3.","Blinded Phase 2 data: 70% of 10 patients at 26 wks had >30% pain reduction, >30% function increase.","No SAEs or dose-limiting toxicity at 26–52 wks; provisional NYSDOH license for allogeneic processing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190497,"accession_number":"0001021771-24-000190","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.","Presentation at Orthopaedic Research Society/Philadelphia Spine Research Society 7th International Spine Research Symposium, Nov 10-14.","Company will host webcasted conference call Nov 13 at 4:30pm ET to review data, Q3 2024 financial results, and provide business update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190496,"accession_number":"0001021771-24-000188","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"BioRestorative enters into $3.6M ATM offering agreement with Rodman & Renshaw; terminates prior JonesTrading ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM agreement with Rodman & Renshaw on Nov 6, 2024 for up to $3.6M of common stock.","Agent will receive 3.0% commission on gross sales proceeds; company not obligated to sell any shares.","Prior ATM with JonesTrading terminated on Nov 1, 2024; $622,235 of shares sold under that agreement.","Offering made under existing effective S-3 registration statement filed Feb 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206990,"accession_number":"0001021771-24-000180","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioRestorative shareholders approve doubling of stock incentive plan shares to 6.85M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I director Nickolay Kukekov re-elected with 2,050,111 votes for, 135,114 withheld, 2,048,738 broker non-votes.","Amendment to 2021 Stock Incentive Plan approved: 1,647,022 for, 518,921 against, 19,282 abstentions, 2,048,738 broker non-votes. Authorized shares increased from 3,850,000 to 6,850,000.","Marcum LLP ratified as auditor for FY2024: 4,152,145 for, 18,696 against, 63,122 abstentions.","Annual meeting held September 19, 2024; all three proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206989,"accession_number":"0001021771-24-000166","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies issues Q2 2024 results press release; specific figures not provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release announcing Q2 2024 financial results was issued on August 13, 2024.","Press release includes a business update and details for a conference call to discuss results.","No specific financial data (revenue, EPS, etc.) are available from the filing text provided.","The filing serves as a notice that results were released, but exhibit content is missing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206988,"accession_number":"0001021771-24-000158","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies schedules Q2 2024 earnings release and call for Aug 13","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Financial results for Q2 2024 will be released after market close on Tuesday, August 13, 2024.","Management will host a conference call following the release to review results and provide a business update.","Press release announcing the schedule was issued on August 6, 2024.","No financial figures or guidance were provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224289,"accession_number":"0001021771-24-000142","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.","Notice has no immediate effect on trading; company has 60 days to submit a plan to regain compliance.","Nasdaq may grant up to 180 calendar days from the 10-Q due date (Nov 11, 2024) for compliance.","Delay stems from ongoing restatement analysis previously disclosed in the May 24, 2024 Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224288,"accession_number":"0001021771-24-000140","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"BioRestorative Therapies restates financials due to warrant classification error; no cash impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.","Restatement reclassifies 2,645,000 public warrants ($10 exercise), 1,856,938 private warrants ($10), and 235,970 underwriter warrants ($12.50) from equity to liabilities.","Non-cash adjustments affect balance sheet and fair value changes in operations; no impact on cash, revenue, operating expenses, or loss from operations.","Company plans to file amended 10-K by June 28, 2024, and concurrently file Q1 2024 10-Q.","Audit committee discussed matter with independent auditor Marcum LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243630,"accession_number":"0001021771-24-000068","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies to present at 36th Annual ROTH Conference on March 18, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Lance Alstodt to participate in fireside chat on March 18, 2024 at 12:00pm PDT.","Fireside chat will be broadcast live and archived on the company's investor relations page.","Management also will hold one-on-one investor meetings during the conference.","Conference takes place March 17-19, 2024 at the Ritz Carlton, Laguna Niguel, Dana Point, CA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243629,"accession_number":"0001021771-24-000033","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BioRestorative raises $8.1M via warrant exercise and new private placement warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.1M from exercise of existing warrants for 3,351,580 shares at $2.33/share.","New warrants issued for up to 2,513,685 shares at $2.43/share, 5-year term, in a private placement.","Proceeds to fund BRTX-100 clinical trials, metabolic ThermoStem R&D, and working capital.","Roth Capital Partners served as financial advisor; fee approx. $528,000.","Existing warrant shares already registered; resale registration for new warrants to be filed within 10 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243628,"accession_number":"0001021771-24-000027","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.","Pain and function scales (VAS, ODI, RMDQ, FRI) show positive trend vs baseline at both follow-up points.","No notable safety signals observed in the ongoing study for chronic lumbar disc disease.","Company will host webcasted conference call today Feb 5 at 8:30am ET to discuss data and clinical update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243627,"accession_number":"0001021771-24-000025","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative to present Phase 2 BRTX-100 data at ORS meeting, host webcast Feb 5","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented at ORS 2024 Annual Meeting Feb 2-6 in Long Beach.","Company will host a webcast conference call with slide presentation on Feb 5, 2024 at 8:30 a.m. ET to review the poster.","No specific efficacy or safety results were disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278298,"accession_number":"0001021771-23-000094","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BRTX stockholders elect directors, approve share increase, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Lance Alstodt and Patrick F. Williams elected with 864,671 and 662,099 votes for, respectively.","Amendment to 2021 Stock Incentive Plan approved: 571,623 for, 276,247 against, 1,907,427 broker non-votes.","Marcum LLP ratified as independent auditor for FY 2023: 2,751,541 for, 15,525 against.","Plan amendment increases authorized shares from 2.5M to 3.85M.","All proposals passed despite significant broker non-votes on director election and plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278297,"accession_number":"0001021771-23-000057","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.","Net proceeds to fund BRTX-100 clinical trials, ThermoStem Program R&D, and general corporate purposes.","Titan Partners Group acting as sole placement agent with 6% cash fee and up to $60K expense reimbursement.","Shares offered under effective S-3 shelf registration (File No. 333-269631)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296423,"accession_number":"0001493152-23-012377","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioRestorative enters ATM equity facility with JonesTrading for up to $3.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Capital On Demand Sales Agreement signed April 14, 2023 with JonesTrading Institutional Services LLC.","Company may sell up to $3.7 million of common stock from time to time in at-the-market offerings.","Agent commission is 3.0% of gross sale proceeds; company not obligated to sell any shares.","Sales will be under existing effective S-3 registration statement (No. 333-269631) filed Feb 2023.","Agreement can be terminated by either party at any time upon notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296422,"accession_number":"0001021771-23-000037","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioRestorative Therapies files accounting firm consents for S-3 registration statement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed consents of Friedman LLP and Marcum LLP to incorporate audit reports into Form S-3.","Consents relate to reports dated March 30, 2022 and March 24, 2023 for 2022 Form 10-K.","Purely administrative filing; no change in financial statements or business operations.","No new financial results, guidance, or events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316895,"accession_number":"0001021771-23-000002","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"BioRestorative Therapies reincorporates from Delaware to Nevada as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation approved by stockholders on Nov 3, 2022; effective Dec 31, 2022 via merger of DE corp into NV subsidiary.","Each outstanding share of common and Series B preferred converted 1:1 into Nevada corporation shares.","Outstanding options, warrants, restricted stock, and equity plans assumed by Nevada corporation on identical terms.","Directors and officers unchanged; no change in business, headquarters, assets, or liabilities.","Stockholder rights modified under Nevada law vs. Delaware; details in Sept 23, 2022 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335145,"accession_number":"0001021771-22-000060","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioRestorative shareholders approve all proposals, including reincorporation to Nevada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected David Rosa and Francisco Silva as Class II directors; 1.8M and 1.95M shares for, respectively.","Approved amendments to 2021 Stock Incentive Plan: 1.79M for, 163K against.","Authorized reincorporation from Delaware to Nevada: 1.95M for, 12K against.","Non-binding advisory vote approved executive compensation; future vote recommended every three years.","Ratified Marcum LLP as independent auditor for FY2022: 2.64M for, 16K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352585,"accession_number":"0001021771-22-000051","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["1.01","4.01","5.03","7.01","9.01"],"status":"ready","headline":"BioRestorative exchanges preferred shares with Auctus, replaces auditor after Friedman/Marcum merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,543,158 Series B preferred shares to Auctus Fund in exchange for same number of Series A shares on Sept 8, 2022.","Series B preferred stock raises beneficial ownership limitation to 9.99% of common stock (up from 4.99% for Series A).","Audit Committee dismissed Friedman LLP and engaged Marcum LLP as independent auditor on Sept 13, 2022, following Friedman's combination with Marcum.","Friedman's reports for FY2020 and FY2021 were unqualified with no disagreements or reportable events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407168,"accession_number":"0001021771-21-000099","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-12-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioRestorative Therapies enters CFO employment agreement with $175K salary, stock option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Robert E. Kristal employment agreement effective Nov 4, 2021, term through Nov 4, 2022.","Annual salary of $175,000; eligible for discretionary bonus up to 30% of salary.","Granted 10-year option to purchase 10,490 shares at $13.50 per share.","Severance: if terminated without cause or resigns for good reason, receives lesser of remaining salary or 25% of current salary, paid over 3 months.","One-year post-employment non-compete covering stem-cell therapy businesses in the US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407167,"accession_number":"0001021771-21-000092","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioRestorative reduces authorized shares to 75M after 1-for-4,000 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction of authorized common shares from 300B to 75M, consistent with the 1-for-4,000 reverse split ratio.","Certificate of Amendment filed with Delaware Secretary of State on November 16, 2021; effective immediately.","Reverse split was previously effected on October 27, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407166,"accession_number":"0001021771-21-000089","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"BioRestorative closes $23M public offering, swaps $10M notes for equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 2.3M units at $10 each, gross proceeds ~$23M. Each unit: 1 common share + 1 warrant.","Exchanged $10.0M convertible notes and $7.8M warrants for 313,780 common shares, 1.54M Series A preferred shares, and new warrants.","Offering and exchange priced at $10.00 per unit; new warrants exercisable at $10 over 5 years.","Common stock now listed on Nasdaq under ticker BRTX.","Roth Capital Partners acted as sole underwriter for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407165,"accession_number":"0001021771-21-000087","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.","Common stock begins trading on Nasdaq Capital Market under symbol BRTX on November 5, 2021.","Appointed Robert E. Kristal as CFO; granted option for 10,490 shares at $13.50; also elected Patrick F. Williams and David Rosa as directors.","Granted options to officers and directors: Alstodt and Silva each received 42,059 shares; also repriced their existing options from $47.60 to $13.50.","Intends to use proceeds for clinical trials of BRTX-100, ThermoStem R&D, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407164,"accession_number":"0001021771-21-000076","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-10-26T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"BioRestorative Therapies announces 1-for-4,000 reverse stock split effective Oct 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved and stockholders authorized a 1-for-4,000 reverse split of common stock.","Effective as of opening of business on October 27, 2021.","Certificate of Amendment filed with Delaware Secretary of State to effect the split.","Press release issued on October 26, 2021 announcing the reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407163,"accession_number":"0001021771-21-000074","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-10-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioRestorative Therapies enters agreements to exchange $9.25M notes and warrants for units in proposed offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged aggregate $9,246,897 principal of convertible notes and warrants for units in proposed public offering.","Auctus Fund exchanged $8,826,952 principal and warrants for 13,766,343,425 shares; lock-up 4 months with 200% price trigger.","Three other holders exchanged $419,945 principal and warrants for 745,643,250 shares; same lock-up terms.","Exchanges conditioned on completion of public offering by January 31, 2022; otherwise agreements terminate.","May issue Series A preferred stock to cap beneficial ownership at 4.99% of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426174,"accession_number":"0001021771-21-000066","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioRestorative Therapies shareholders approve reverse stock split, reject Nevada reincorporation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Nickolay Kukekov as Class I director: 1.49B for, 132.6M withheld, 452M broker non-votes.","Approved 2021 Stock Incentive Plan: 1.33B for, 210M against, 80.8M abstentions.","Rejected reincorporation from Delaware to Nevada: 1.48B for but 4.4M abstentions, needed majority; broker non-votes 452M.","Authorized Board to effect reverse stock split at ratio 1:20 to 1:4000 with discretion; 1.65B for, 396M against.","Ratified Friedman LLP as auditor for FY2021: 1.93B for, 90.2M against, 50M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}